Review Article
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Table 5
Selected clinical
trials of sorafenib. PFS,
progression free survival; OS, overall survival; PR, partial
response; CR, complete response; HCC, hepatocellular carcinoma; RCC,
renal cell carcinoma; TBRR, Tumor burden reduction rate.
| | Malignancy | Regimen | Number of patients | Response rate | Comments |
| | RCC | Sorafenib vs. placebo
[41] | 903
Resistant to standard therapy | Sorafenib:
Median PFS (5.5 mo) PR (10%)
Placebo: Median PFS (2.8 mo)
PR (2%) | The OS showed reduced risk of
death compared with placebo but the results were not statistically
significant |
| | HCC | Sorafenib vs. placebo
[42] | 602 pts
No previous therapy | Sorafenib:
Median OS (10.7 mo) Placebo:
Median OS (7.9 mo) | The median OS was
significantly longer in patients who received Sorafenib
HR (0.69), |
| | Metastatic thyroid carcinoma | Sorafenib monotherapy [45] | 36 pts
Metastatic, iodine-refractory
thyroid carcinoma | PR in 7 pts (21%) SD in 20 pts (59%) | Significant anti-tumor
activity with overall clinical benefit rate (PR + SD) of 80% |
|
|
